183 related articles for article (PubMed ID: 28551040)
1. Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant.
Toprani VM; Sahni N; Hickey JM; Robertson GA; Middaugh CR; Joshi SB; Volkin DB
Vaccine; 2017 Oct; 35(41):5471-5480. PubMed ID: 28551040
[TBL] [Abstract][Full Text] [Related]
2. Structural Characterization and Physicochemical Stability Profile of a Double Mutant Heat Labile Toxin Protein Based Adjuvant.
Toprani VM; Hickey JM; Sahni N; Toth RT; Robertson GA; Middaugh CR; Joshi SB; Volkin DB
J Pharm Sci; 2017 Dec; 106(12):3474-3485. PubMed ID: 28780391
[TBL] [Abstract][Full Text] [Related]
3. Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentration.
Estrada MR; Bzami A; Norton EB; White JA
Vaccine; 2023 Feb; 41(7):1362-1367. PubMed ID: 36658044
[TBL] [Abstract][Full Text] [Related]
4. The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens.
Leach S; Clements JD; Kaim J; Lundgren A
PLoS One; 2012; 7(12):e51718. PubMed ID: 23284753
[TBL] [Abstract][Full Text] [Related]
5. Preformulation studies with the Escherichia coli double mutant heat-labile toxin adjuvant for use in an oral vaccine.
White JA; Haghighi C; Brunner J; Estrada M; Lal M; Chen D
J Immunol Methods; 2017 Dec; 451():83-89. PubMed ID: 28939395
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant effect of enterotoxigenic
Seo H; Lu T; Mani S; Bourgeois AL; Walker R; Sack DA; Zhang W
Hum Vaccin Immunother; 2020; 16(2):419-425. PubMed ID: 31361177
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
[TBL] [Abstract][Full Text] [Related]
8. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.
Summerton NA; Welch RW; Bondoc L; Yang HH; Pleune B; Ramachandran N; Harris AM; Bland D; Jackson WJ; Park S; Clements JD; Nabors GS
Vaccine; 2010 Feb; 28(5):1404-11. PubMed ID: 19897067
[TBL] [Abstract][Full Text] [Related]
9. Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients.
Stone AE; Rambaran S; Trinh IV; Estrada M; Jarand CW; Williams BS; Murrell AE; Huerter CM; Bai W; Palani S; Nakanishi Y; Laird RM; Poly FM; Reed WF; White JA; Norton EB
Vaccine; 2023 Feb; 41(9):1589-1601. PubMed ID: 36732163
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
[TBL] [Abstract][Full Text] [Related]
11. U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge.
Coria LM; Martinez FL; Bruno LA; Pasquevich KA; Cassataro J
Vaccine; 2020 Jul; 38(32):5027-5035. PubMed ID: 32536545
[TBL] [Abstract][Full Text] [Related]
12. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
[TBL] [Abstract][Full Text] [Related]
13. Immunization with a Double-Mutant (R192G/L211A) of the Heat-Labile Enterotoxin of Escherichia coli Offers Partial Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model.
Albert MJ; Haridas S; Ebenezer M; Raghupathy R; Khan I
PLoS One; 2015; 10(11):e0142090. PubMed ID: 26540197
[TBL] [Abstract][Full Text] [Related]
14. dmLT Adjuvant Enhances Cytokine Responses to T Cell Stimuli, Whole Cell Vaccine Antigens and Lipopolysaccharide in Both Adults and Infants.
Akhtar M; Nizam NN; Basher SR; Hossain L; Akter S; Bhuiyan TR; Qadri F; Lundgren A
Front Immunol; 2021; 12():654872. PubMed ID: 34054818
[TBL] [Abstract][Full Text] [Related]
15. The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.
Clements JD; Norton EB
mSphere; 2018 Jul; 3(4):. PubMed ID: 30045966
[TBL] [Abstract][Full Text] [Related]
16. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.
Sjökvist Ottsjö L; Flach CF; Clements J; Holmgren J; Raghavan S
Infect Immun; 2013 May; 81(5):1532-40. PubMed ID: 23439305
[TBL] [Abstract][Full Text] [Related]
17. Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.
Agarwal S; Sahni N; Hickey JM; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
J Pharm Sci; 2020 Jan; 109(1):394-406. PubMed ID: 31400346
[TBL] [Abstract][Full Text] [Related]
18. Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity.
Ruan X; Sack DA; Zhang W
PLoS One; 2015; 10(3):e0121623. PubMed ID: 25803825
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.
Norton EB; Lawson LB; Freytag LC; Clements JD
Clin Vaccine Immunol; 2011 Apr; 18(4):546-51. PubMed ID: 21288994
[TBL] [Abstract][Full Text] [Related]
20. Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia.
Baker SM; Pociask D; Clements JD; McLachlan JB; Morici LA
Vaccine; 2019 Feb; 37(6):808-816. PubMed ID: 30638799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
